United States AMD Drug Market 2025: Get Exclusive Data | Top 5 Companies are Regeneron Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Kubota Pharmaceutical Holdings Inc., AbbVie Inc

Global AMD Drugs Market was valued at US$ 9,717.64 million in 2021 and is estimated to reach US$ 15,903.86 million by 2031, growing at a CAGR of 7.26% during the forecast period (2024-2031).

United States AMD Market size in 2024: USD 5.0 B and projection to USD 8.72 B by 2030, CAGR 7.8%

Japan AMD Market size in 2024: USD 0.524 B and projection to USD 0.896 B by 2033, CAGR 6.9%

According to the American Academy of Ophthalmology, the cost per treatment for Beovu, Lucentis, and Eylea ranges from approximately $1,800 to $2,000, while Avastin costs around $50 per treatment.

The prevalence of ADM is projected to increase, reaching an estimated 288 million cases by 2040.

United States: Recent Industry Developments
✅ October 2025: Regeneron Pharmaceuticals received FDA approval for a new long-acting injectable drug for wet AMD treatment.
✅ September 2025: Novartis launched a gene therapy clinical trial targeting dry AMD progression.
✅ August 2025: Advancements in anti-VEGF therapies improved dosing frequency and patient compliance.

Japan: Recent Industry Developments
✅ October 2025: Santen Pharmaceutical expanded its AMD drug portfolio with innovative biologics focusing on retinal protection.
✅ September 2025: Collaborative research in Japan explored stem cell therapies for AMD treatment.
✅ August 2025: Increasing adoption of teleophthalmology solutions enhanced early diagnosis and treatment follow-up.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/amd-drugs-market?kb

Latest M&A Activity

The pharma sector continues consolidation with companies like Roche and Regeneron expanding their AMD portfolio through partnerships and licensing deals, though no major blockbuster AMD-specific acquisitions were reported in the last quarter.​

Contract Development and Manufacturing Organizations (CDMOs) supporting AMD drug production have seen increased M&A activity to meet growing demand and complex biologics manufacturing.

Key Players:

Bayer HealthCare LLC, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Kubota Pharmaceutical Holdings Inc., AbbVie Inc., Kodiak Sciences, Genentech Inc., Roche Group Member, Regenxbio Inc.

Growth Forecast Projected:

The Global AMD Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Clinical Trials and Pipeline

Phase 3 clinical trials such as LUNA (Ixo-vec), STAR (Efdamrofusp alfa), and DAYLIGHT (tarcocimab) are ongoing to evaluate extended efficacy and safety profiles of next-generation AMD drugs, involving mechanisms like dual VEGF and complement inhibition or antibody biopolymer conjugates.​

Innovative therapies in the clinical pipeline include gene therapies, bispecific antibodies targeting VEGF and Ang-2, and novel sustained-release delivery methods aiming at improving long-term visual outcomes

Research Process:

Both primary and secondary data sources have been used in the global AMD Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=amd-drugs-market?kb

Key Segments:

By Product Type: (Wet AMD, Dry AMD)

By Drug Type: (Lucentis, Eylea, Avastin, Others)

By Route of Administration: (Intravenous, Intravitreal)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among AMD Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze AMD Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/amd-drugs-market?kb

Recent Product Launches and Approvals

FDA-approved drugs like Vabysmo (faricimab) and Beovu (brolucizumab) are gaining market traction, offering extended dosing intervals (3-4 months for Vabysmo and 8-12 weeks for Beovu), significantly reducing treatment burden.​

Novartis is advancing susvimo, an implantable ranibizumab delivery system providing continuous drug release, improving adherence and reducing injections needed.​

Recent advancement includes pegcetacoplan (Syfovre), first approved in 2023 for geographic atrophy secondary to AMD, with ongoing trials exploring expanded indications.

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.